TABLE 3 ].
Descriptive Statistics for Patients With Pulmonary Hypertension
| Variable | No. | Male (n = 279) | Female (n = 471) | P Value |
|---|---|---|---|---|
| Age, y | ||||
| At enrollment | 750 | 60.7 ± 14.5 | 57.1 ± 14.7 | .001a |
| At diagnosis | 748 | 57.7 ± 16.6 (n = 279) | 53.1 ± 16.8 (n = 469) | < .001a |
| Prevalent cases | 748 | 201 (72.0) | 349 (74.4) | .48b |
| Duration of PH in prevalent cases, y | 748 | 2.2 (0.8–5.5) (n = 201) | 3.5 (1.1–8.2) (n = 349) | .02a |
| BMI, kg/m2 | 750 | 29.9 ± 6.8 | 30.2 ± 8.6 | .43a |
| Measured body fat, % | 497 | 28.1 ± 9.9 (n = 176) | 38.0 ± 10.7 (n = 321) | < .001a |
| WHO functional class | 723 | … | … | .99b |
| I | … | 20 (7.4) | 32 (7.0) | … |
| II | … | 93 (34.6) | 155 (34.1) | … |
| III | … | 143 (53.2) | 243 (53.5) | … |
| IV | … | 13 (4.8) | 24 (5.3) | … |
| PH treatments | 746 | … | … | … |
| Any | … | 136 (49.3) | 288 (61.3) | .001b |
| PDE-5 inhibitor | … | 109 (39.5) | 221 (47.0) | .046b |
| sGC stimulator | … | 13 (4.7) | 27 (5.7) | .55b |
| ERA | … | 63 (22.8) | 170 (36.2) | < .001b |
| Prostacyclin | … | 46 (16.7) | 134 (28.5) | < .001b |
| Calcium channel blocker | … | 2 (0.7) | 18 (3.8%) | .01c |
| Diuretic therapy | … | 165 (59.8) | 288 (63.4) | .33b |
| History of coronary disease (MI or coronary artery bypass) | 746 | 50 (18.0) | 19 (4.1) | < .001b |
| Diabetes mellitus | 746 | 75 (27.0) | 105 (22.4) | .16b |
| Chronic kidney disease | 745 | 28 (10.1) | 33 (7.1) | .15b |
| Hypertension | 745 | 134 (48.2) | 190 (40.7) | .045b |
| History of atrial arrhythmias | 746 | 66 (23.7) | 87 (18.6) | .09b |
| Current smoking or history of smoking | 745 | 166 (60.1) | 203 (43.3) | < .001b |
| DLCO, % predicted | 657 | 45.7 ± 20.8 (n = 242) | 55.6 ± 21.6 (n = 415) | < .001a |
| FEV1, % predicted | 678 | 69.4 ± 22.3 (n = 246) | 72.3 ± 20.1 (n = 432 | .13a |
| FVC, % predicted | 678 | 78.3 ± 20.7 (n = 246) | 78.7 ± 19.6 (n = 432) | .77a |
| 6-min walk distance, m | 621 | 350 ± 135 (n = 232) | 347 ± 135 (n = 389) | .67a |
| NT-proBNP, pg/mL | 722 | 464 (119–1,441) (n = 269) | 280 (102–1,231) (n = 453) | .04a |
Data presented as No. (%), mean ± SD, or median (interquartile range) unless otherwise indicated. The n values are the number of nonmissing values. Numbers after proportions are frequencies. DLCO = diffusing capacity of the lungs for carbon monoxide; ERA = endothelin receptor antagonist; MI myocardial infarction; NT-proBNP = N-terminal fragment of the prohormone brain-type natriuretic peptide; PDE-5 = phosphodiesterase-5; PH = pulmonary hypertension; sGC = soluble guanylate cyclase stimulator; WHO = World Health Organization.
a
Wilcoxon rank-sum test.
b
Pearson χ2 test.
c
Fisher exact test.